Published in Hepatitis Weekly, May 21st, 2001
Lamivudine, a drug commonly used for treating patients with hepatitis B virus (HBV), is not effective in all patients. A new study proposes that by quantifying HBV levels and examining serum samples for virus mutations, physicians could get an early indication of whether lamivudine therapy will be effective in patients with chronic hepatitis B.
Maria Buti, lead investigator of the current study, and coworkers at the Universidad Valle de Hebron in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.